自体造血干细胞移植桥接CAR-T细胞疗法在多发性骨髓瘤的研究进展

韩 相宜1, 马红 梅*2
1、承德医学院
2、沧州市人民医院　血液科

摘要


多发性骨髓瘤的治疗已进入免疫治疗新时代，而ASCT与CAR-T疗法的序贯整合代表了当前最具前景的治疗策略之一。在序贯策略中，桥接治疗发挥着承前启后的关键作用。高强度细胞毒性桥接治疗虽能快速控制疾病，但可能损害后续造血恢复，而自体干细胞回输可改善血细胞减少、G-CSF支持也可降低感染风险。此外，不同序贯疗法各有其适用场景，但序贯疗法的最佳时序仍需要进一步探索。

关键词


桥接治疗；CAR-T；多发性骨髓瘤；自体造血干细胞移植

全文:

PDF


参考


[1]Parikh R H, Lonial S. Chimeric antigen receptor T‐cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice[J]. CA: A Cancer Journal for Clinicians, 2023, 73(3): 275-285.

[2]Richardson T, Holtick U, Frenking J H, et al. Sequential BCMA CAR-T Cell Therapy in Refractory Multiple Myeloma[J]. Blood Advances, 2025: bloodadvances. 2025016712.

[3]Joseph N S, Kaufman J L, Dhodapkar M V, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma[J]. Journal of Clinical Oncology, 2020, 38(17): 1928-1937.

[4]Holstein S A, Grant S J, Wildes T M. Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future[J]. Journal of Clinical Oncology, 2023, 41(27): 4416-4429.

[5]Mohty M, Dulery R, Gauthier J, et al. CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview[J]. Bone Marrow Transplantation, 2020, 55(8): 1525-1532.

[6]Kumar S K, Callander N S, Adekola K, et al. NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025: Featured Updates to the NCCN Guidelines®[J]. Journal of the National Comprehensive Cancer Network, 2025, 23(5): 132-140.

[7]Manjunath S H, Cohen A D, Lacey S F, et al. The safety of bridging radiation with anti-BCMA CAR T-cell therapy for multiple myeloma[J]. Clinical Cancer Research, 2021, 27(23): 6580-6590.

[8]Wang Y, Cao J, Gu W, et al. Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma[J]. Journal of Clinical Oncology, 2022, 40(20): 2246-2256.

[9]Frenking J H, Zhou X, Rejeski K, et al. Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myeloma[J]. Blood advances, 2025: bloodadvances. 2024015732.

[10]Molinos-Quintana Á, Martínez-Cibrian N, Alonso-Saladrigues A, et al. Successful allogeneic CD34+ hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)[J]. Bone Marrow Transplantation, 2025, 60(2): 250-253.

[11]Oosterink K A, Dekker T J A, Tjon J M L, et al. Filgrastim after autologous stem cell transplantation shortens time to neutrophil recovery and hospital stay[J]. Annals of Hematology, 2025: 1-3.

[12]Ding M J, Jie X X, Li H J, et al. Impact of autologous hematopoietic stem cell transplantation on the efficacy of CAR-T treatment of relapsed/refractory multiple myeloma[J]. Zhonghua nei ke za zhi, 2024, 63(6): 587-592.


Refbacks

  • 当前没有refback。